drugset / Trial / NCT05521997
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Phase 2
Not yet recruiting
42 enrolled
Washington University School of Medicine
Calithera Biosciences, Inc · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Timeline
- Start
- 2026-07-31
- Primary completion
- 2032-10-07
- Completion
- 2032-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB-839 | Unknown | 800 mg | Oral |
| Background | Cisplatin | Other / unclassified | — | — |